Form 4: Vaxcyte CFO Sells Shares for Tax Obligations

Vaxcyte's President and CFO, Andrew Guggenhime, disposed of 2,890 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Andrew Guggenhime, President and CFO of Vaxcyte, Inc., reported a transaction on September 8, 2025.
• The transaction involved the disposition of 2,890 shares of Vaxcyte Common Stock.
• These shares were surrendered to the Issuer to cover tax withholding obligations upon the vesting of Restricted Stock Units (RSUs).
• The shares were valued at $32.41 per share for this transaction.
• Following this transaction, Andrew Guggenhime directly beneficially owns 124,309 shares of Vaxcyte Common Stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: Neutral. This is a routine, non-discretionary transaction for tax purposes related to RSU vesting, which is a common occurrence for executives and does not reflect a change in sentiment towards the company's prospects.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-arranged, compliant disposition.
• The disposition was for tax withholding, a routine event for RSU vesting, not an open-market sale for personal liquidity.

Negatives

• A reduction in direct beneficial ownership by a key executive, although for tax purposes, slightly decreases insider holdings.

Future Outlook

No specific future outlook or guidance is provided.

Industry Context

This is a routine insider transaction for tax purposes, common across all industries, especially in sectors like biotechnology where RSU compensation is prevalent. It does not indicate specific industry trends.

Comparison to Industry Standards

• The use of a Rule 10b5-1(c) plan for executive stock transactions is standard practice for managing insider trading compliance across publicly traded companies, including peers like Moderna (MRNA) or BioNTech (BNTX) in the biotechnology sector.
• Dispositions for tax withholding upon RSU vesting are a common and expected event for executives receiving equity compensation, aligning with practices at companies such as Pfizer (PFE) or Johnson & Johnson (JNJ).

Related Party Transactions

• The transaction involves the surrender of shares to the Issuer (Vaxcyte, Inc.) to cover tax withholding obligations, which is a common type of related-party transaction in the context of executive equity compensation.

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, but for a routine tax purpose, so minimal impact.
• Employees: No direct impact.
• Customers: No direct impact.
• Suppliers: No direct impact.
• Creditors: No direct impact.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary transaction by an executive to cover tax obligations upon RSU vesting. Such transactions are common and do not typically signal a change in the company's fundamentals or the executive's confidence. Therefore, it provides no new information to warrant a change in investment thesis, suggesting a 'hold' recommendation based solely on this filing.

Keywords

Vaxcyte, PCVX, Andrew Guggenhime, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Tax Withholding, Biotechnology, Pharmaceuticals